Anika Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Anika Therapeutics Inc. (ANIK)
Last anika therapeutics inc. earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anikatherapeutics.com/investor-relations
Company Research
Source: Yahoo! Finance
the commercial channel (to $13.3M ) offset a 12% OEM decline, full-year revenue fell 6% to $112.8M , and management guided 2026 revenue of $114M–$122.5M with 5%–10% adjusted EBITDA. Pipeline momentum with regulatory hurdles: Surgical product Integrity more than doubled to about $6M in 2025 (over 2,500 surgeries to date), Cingal passed one million injections and is running a ~60-patient bioequivalence study, while Hyalofast's PMA was filed but Phase III missed pre-specified co-primary endpoints and the FDA issued a CMC/clinical-data deficiency letter. Profitability, cash and cost actions: Q4 gross margin improved to and adjusted EBITDA was positive ( $4.5M Q4; $5.3M FY), the company ended 2025 with $57.5M cash and no debt plus a $15M buyback plan, and is implementing organizational changes expected to save roughly $2.5M in headcount and over $3M in stock-based comp. Interested in Anika Therapeutics Inc.? Here are five stocks we like better. Anika Therapeutics (NASDAQ:ANIK) deta
Show less
Read more
Impact Snapshot
Event Time:
ANIK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIK alerts
High impacting Anika Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ANIK
News
- Anika Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Anika Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
- Anika To Present at the Canaccord Genuity 2026 Musculoskeletal ConferenceGlobeNewswire
- Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026GlobeNewswire
- Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors [Yahoo! Finance]Yahoo! Finance
ANIK
Earnings
- 2/26/26 - Beat
ANIK
Sec Filings
- 2/26/26 - Form 8-K
- 2/3/26 - Form 4
- 1/27/26 - Form SCHEDULE
- ANIK's page on the SEC website